Interleukin-6 selectively induces drug metabolism to potentiate the genotoxicity of dietary carcinogens in mammary cells

Arch Toxicol. 2019 Oct;93(10):3005-3020. doi: 10.1007/s00204-019-02558-8. Epub 2019 Sep 12.

Abstract

Breast cancer is the most commonly diagnosed malignancy in females, the etiology being multifactorial and includes the role of lifestyle exposure to DNA-damaging chemicals such as dietary carcinogens benzo (a) pyrene (BaP) and 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP). Both compounds require cytochrome P450 (CYP)-mediated metabolic activation to DNA-damaging species, and both induce transcriptional responses through the nuclear receptors Aryl hydrocarbon receptor (AhR) and estrogen receptor α (ERα). BaP and PhIP are mammary carcinogens in rodents. Clinically, circulating IL-6 expression is linked with poor prognosis of cancer and 35% of the deaths in breast cancer are linked with inflammation. The objective of this work was to investigate the molecular toxicology and local activation of BaP and PhIP in the presence of IL-6. Our laboratory has previously reported that miR27b can regulate CYP1B1 expression in colorectal cells, here we have investigated if this mechanism is working in mammary cell models, MCF-7 and MDA-MB-231 cells. Treatment (24 h) of cells with BaP (10 nM-10 µM) and PhIP (100 nM-100 µM) significantly induced genetic damage (micronuclei formation) in a dose-dependent manner in both cell lines. This effect was potentiated in the presence of human IL-6 at concentrations reported to be expressed in clinical breast cancer. On its own, IL-6 treatment failed to induce micronuclei frequency above the control levels in these cells. Compared to BaP or PhIP treatment alone, IL-6 plus BaP or PhIP selectively induced CYP1B1 significantly in both cell lines. Additionally, miR27b expression was downregulated by IL-6 treatments and transfection with miR27b inhibitor confirmed that miR27b is a regulator of CYP1B1 in both cell lines. These data show that BaP- and PhIP-induced DNA damage in mammary cells is potentiated by the inflammatory cytokine IL-6 and that inflammation-induced CYP expression, specifically CYP1B1 via miR27b, is responsible for this effect.

Keywords: 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine; Benzo(a)pyrene; Genotoxicity; Human mammary cells; IL-6; Inflammation; miRNA.

MeSH terms

  • Benzo(a)pyrene / administration & dosage
  • Benzo(a)pyrene / toxicity*
  • Breast Neoplasms / genetics
  • Breast Neoplasms / pathology*
  • Carcinogens / administration & dosage
  • Carcinogens / toxicity*
  • Cell Line, Tumor
  • Cytochrome P-450 CYP1B1 / genetics
  • DNA Damage / drug effects
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Imidazoles / administration & dosage
  • Imidazoles / toxicity*
  • Inflammation / complications
  • Interleukin-6 / administration & dosage
  • Interleukin-6 / metabolism*
  • MCF-7 Cells
  • MicroRNAs / genetics

Substances

  • Carcinogens
  • Imidazoles
  • Interleukin-6
  • MIRN27 microRNA, human
  • MicroRNAs
  • Benzo(a)pyrene
  • 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
  • CYP1B1 protein, human
  • Cytochrome P-450 CYP1B1